Findings support saRNA as a therapeutic strategy to compensate dystrophin’s function by upregulating UTRN expression…
EnvisionNovember 2, 2023
Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s…
EnvisionJune 10, 2023
Event: 2023 American Society of Clinical Oncology Meeting (Chicago) View Abstract
EnvisionJune 7, 2023
Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…
EnvisionMarch 3, 2023
Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…
EnvisionJanuary 27, 2022
Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…
EnvisionFebruary 10, 2021
